Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE44.1100
- TODAY'S CHANGE (%)-2.6600 (-5.6874%)
- Bid / Lots43.8900/ 1
- Ask / Lots44.5000/ 1
- Open / Previous Close45.4200 / 46.7700
- Day Range
- 52 Week Range
- Volume804,770
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 17193 | 45.32 |
| 09:34 ET | 1181 | 45.07 |
| 09:36 ET | 5216 | 44.9 |
| 09:38 ET | 900 | 44.8 |
| 09:39 ET | 600 | 44.73 |
| 09:41 ET | 2298 | 45.05 |
| 09:43 ET | 3797 | 45.13 |
| 09:45 ET | 2754 | 45.24 |
| 09:48 ET | 2780 | 45.045 |
| 09:50 ET | 1645 | 45.035 |
| 09:52 ET | 1100 | 45.05 |
| 09:54 ET | 4600 | 45.31 |
| 09:56 ET | 700 | 45.025 |
| 09:57 ET | 1101 | 45.069 |
| 09:59 ET | 1272 | 44.845 |
| 10:01 ET | 600 | 44.8 |
| 10:03 ET | 620 | 44.75 |
| 10:06 ET | 4150 | 45.065 |
| 10:08 ET | 1100 | 45.22 |
| 10:10 ET | 700 | 45.12 |
| 10:12 ET | 822 | 45.08 |
| 10:14 ET | 271 | 45 |
| 10:15 ET | 1282 | 45.13 |
| 10:17 ET | 1116 | 45.245 |
| 10:19 ET | 707 | 45.27 |
| 10:21 ET | 10805 | 45.39 |
| 10:24 ET | 300 | 45.35 |
| 10:26 ET | 231 | 45.46 |
| 10:28 ET | 500 | 45.635 |
| 10:30 ET | 320 | 45.76 |
| 10:32 ET | 1482 | 45.695 |
| 10:33 ET | 400 | 45.51 |
| 10:37 ET | 1959 | 45.59 |
| 10:42 ET | 2304 | 45.35 |
| 10:44 ET | 377 | 45.475 |
| 10:46 ET | 400 | 45.58 |
| 10:48 ET | 1149 | 45.88 |
| 10:50 ET | 1368 | 45.795 |
| 10:51 ET | 500 | 45.69 |
| 10:53 ET | 224 | 45.685 |
| 10:55 ET | 500 | 45.765 |
| 11:00 ET | 200 | 45.775 |
| 11:02 ET | 700 | 45.82 |
| 11:06 ET | 1342 | 45.65 |
| 11:08 ET | 900 | 45.705 |
| 11:09 ET | 1100 | 45.72 |
| 11:11 ET | 500 | 45.78 |
| 11:13 ET | 398 | 45.745 |
| 11:15 ET | 1353 | 45.655 |
| 11:18 ET | 1100 | 45.595 |
| 11:20 ET | 1495 | 45.44 |
| 11:22 ET | 800 | 45.445 |
| 11:24 ET | 800 | 45.425 |
| 11:26 ET | 1000 | 45.52 |
| 11:29 ET | 1300 | 45.545 |
| 11:31 ET | 1374 | 45.56 |
| 11:33 ET | 1100 | 45.43 |
| 11:36 ET | 13100 | 45.72 |
| 11:38 ET | 1234 | 45.705 |
| 11:40 ET | 700 | 45.62 |
| 11:42 ET | 1200 | 45.5 |
| 11:44 ET | 100 | 45.44 |
| 11:45 ET | 500 | 45.55 |
| 11:51 ET | 1500 | 45.4 |
| 11:54 ET | 400 | 45.39 |
| 11:56 ET | 600 | 45.445 |
| 11:58 ET | 1761 | 45.47 |
| 12:00 ET | 939 | 45.44 |
| 12:02 ET | 685 | 45.415 |
| 12:03 ET | 400 | 45.38 |
| 12:05 ET | 200 | 45.36 |
| 12:07 ET | 1700 | 45.37 |
| 12:09 ET | 1500 | 45.505 |
| 12:12 ET | 700 | 45.64 |
| 12:16 ET | 1823 | 45.58 |
| 12:18 ET | 1200 | 45.605 |
| 12:20 ET | 150 | 45.6 |
| 12:21 ET | 997 | 45.52 |
| 12:23 ET | 100 | 45.5 |
| 12:25 ET | 506 | 45.395 |
| 12:30 ET | 100 | 45.385 |
| 12:32 ET | 400 | 45.27 |
| 12:34 ET | 100 | 45.21 |
| 12:36 ET | 400 | 45.2 |
| 12:38 ET | 100 | 45.19 |
| 12:39 ET | 1244 | 45.28 |
| 12:43 ET | 600 | 45.25 |
| 12:48 ET | 200 | 45.22 |
| 12:54 ET | 1300 | 45.11 |
| 12:57 ET | 800 | 45.1397 |
| 12:59 ET | 1400 | 45.21 |
| 01:01 ET | 493 | 45.21 |
| 01:03 ET | 611 | 45.17 |
| 01:06 ET | 100 | 45.12 |
| 01:08 ET | 100 | 45.21 |
| 01:10 ET | 300 | 45.18 |
| 01:12 ET | 500 | 45.14 |
| 01:14 ET | 100 | 45.175 |
| 01:15 ET | 559 | 45.06 |
| 01:17 ET | 700 | 45.045 |
| 01:19 ET | 4504 | 45.005 |
| 01:21 ET | 300 | 45.01 |
| 01:24 ET | 600 | 44.995 |
| 01:26 ET | 943 | 44.93 |
| 01:28 ET | 900 | 44.94 |
| 01:30 ET | 1683 | 45.11 |
| 01:32 ET | 400 | 45.095 |
| 01:33 ET | 100 | 45.08 |
| 01:35 ET | 1052 | 45.055 |
| 01:37 ET | 939 | 45.11 |
| 01:42 ET | 1200 | 45.015 |
| 01:44 ET | 1654 | 45.02 |
| 01:46 ET | 700 | 45.005 |
| 01:50 ET | 100 | 44.97 |
| 01:53 ET | 504 | 44.96 |
| 01:55 ET | 1500 | 44.89 |
| 01:57 ET | 400 | 44.78 |
| 02:00 ET | 712 | 44.78 |
| 02:02 ET | 700 | 44.77 |
| 02:04 ET | 400 | 44.72 |
| 02:06 ET | 700 | 44.785 |
| 02:08 ET | 1300 | 44.72 |
| 02:09 ET | 6805 | 44.6 |
| 02:11 ET | 2094 | 44.62 |
| 02:13 ET | 804 | 44.58 |
| 02:18 ET | 1245 | 44.59 |
| 02:20 ET | 400 | 44.59 |
| 02:22 ET | 100 | 44.595 |
| 02:24 ET | 907 | 44.59 |
| 02:26 ET | 400 | 44.63 |
| 02:27 ET | 1977 | 44.635 |
| 02:29 ET | 1878 | 44.63 |
| 02:31 ET | 7821 | 44.54 |
| 02:33 ET | 463 | 44.545 |
| 02:36 ET | 325 | 44.545 |
| 02:38 ET | 9454 | 44.54 |
| 02:40 ET | 1700 | 44.49 |
| 02:42 ET | 34529 | 44.4 |
| 02:44 ET | 400 | 44.36 |
| 02:45 ET | 924 | 44.29 |
| 02:47 ET | 1628 | 44.28 |
| 02:49 ET | 4493 | 44.355 |
| 02:51 ET | 8866 | 44.4 |
| 02:54 ET | 2537 | 44.37 |
| 02:56 ET | 16589 | 44.53 |
| 02:58 ET | 2066 | 44.49 |
| 03:00 ET | 2937 | 44.545 |
| 03:02 ET | 3220 | 44.565 |
| 03:03 ET | 4600 | 44.67 |
| 03:05 ET | 5190 | 44.535 |
| 03:07 ET | 2791 | 44.55 |
| 03:09 ET | 1307 | 44.545 |
| 03:12 ET | 2480 | 44.39 |
| 03:14 ET | 1320 | 44.4 |
| 03:16 ET | 500 | 44.26 |
| 03:18 ET | 722 | 44.225 |
| 03:20 ET | 4573 | 44.08 |
| 03:21 ET | 1226 | 44.08 |
| 03:23 ET | 5414 | 44.1525 |
| 03:25 ET | 1507 | 44.099 |
| 03:27 ET | 6575 | 44.06 |
| 03:30 ET | 1900 | 44.055 |
| 03:32 ET | 7004 | 44.225 |
| 03:34 ET | 4212 | 44.39 |
| 03:36 ET | 3525 | 44.415 |
| 03:38 ET | 1737 | 44.31 |
| 03:39 ET | 3218 | 44.3 |
| 03:41 ET | 6392 | 44.3 |
| 03:43 ET | 4864 | 44.225 |
| 03:45 ET | 3395 | 44.08 |
| 03:48 ET | 4001 | 44.05 |
| 03:50 ET | 7212 | 44.03 |
| 03:52 ET | 5585 | 44.06 |
| 03:54 ET | 8711 | 44.11 |
| 03:56 ET | 10539 | 44.04 |
| 03:57 ET | 18568 | 44.03 |
| 03:59 ET | 35653 | 44.11 |
Jun 13, 2024
DJ Agios Pharmaceuticals Price Target Announced at $46.00/Share by JP Morgan, from 5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 6, 2024
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET, from 9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
Jun 4, 2024
DJ Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 11:26AM ET on Tuesday Jun 04, 2024 by Dow Jones
11:26AM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
DJ Agios Pharmaceuticals Shares Rise 16% After Positive Trial Data for Mitapivat, from 10:25AM ET on Monday Jun 03, 2024 by Dow Jones
10:25AM ET on Monday Jun 03, 2024 by Dow JonesAgios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia, from 6:30AM ET on Monday Jun 03, 2024 by Dow Jones
6:30AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.5B | -7.0x | --- |
Intellia Therapeutics Inc | 2.4B | -4.7x | --- |
Apogee Therapeutics Inc | 2.4B | -20.1x | --- |
MoonLake Immunotherapeutics | 2.6B | -55.2x | --- |
Celldex Therapeutics Inc | 2.3B | -12.2x | --- |
CG Oncology Inc | 2.3B | -30.8x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
|---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | 85.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
